Q2 2025 Grail Inc Earnings Call Transcript
Key Points
- GRAIL Inc (GRAL) reported a strong revenue growth of 11% in the second quarter of 2025, reaching $35.5 million.
- The company sold more than 45,000 Galleri tests in the second quarter, indicating strong demand and commercial growth.
- GRAIL Inc (GRAL) has established partnerships with major health systems, including Rush University System for Health, to expand the availability of the Galleri test.
- The PATHFINDER 2 study showed a substantially higher positive predictive value and greater additional cancer detection compared to the first PATHFINDER study.
- The company has a strong cash position of $606.1 million, with a cash runway extending into 2028, allowing for continued investment in clinical and regulatory milestones.
- GRAIL Inc (GRAL) reported a net loss of $114 million for the quarter, although this was an improvement compared to the previous year.
- The company experienced increased turnaround times and higher reprocessing costs for a small proportion of samples due to the complexity of their new automated platform.
- There are ongoing challenges with achieving broad reimbursement for the Galleri test, which is crucial for long-term commercial success.
- The company faces risks and uncertainties related to the FDA approval process for the Galleri test, which is expected to take about a year.
- GRAIL Inc (GRAL) has not yet normalized the positive predictive value for cancer prevalence in their studies, which could impact the interpretation of their results.
Good day ladies and gentlemen, and welcome to the GRAIL second quarter 2025 earnings call. (Operator Instructions) Please be advised that this conference call is being recorded. GRAIL Investor Relations, please begin.
Thanks, operator, and thanks, everyone, for joining us today. On the call are Bob Ragusa, our Chief Executive Officer; Aaron Freidin, our Chief Financial Officer; Dr. Joshua Ofman, our President; Sir Harpal Kumar, our President, International Business in Biopharma; and Andy Partridge, our Chief Commercial Officer.
We'll be making forward-looking statements on this call based on current expectations. It's our intent that all statements other than statements of historical fact made during today's call, including statements regarding our anticipated financial results and commercial activity will be covered by the Safe Harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 as amended and Section 21 of the Securities Exchange Act of 1934, as amended.
Forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
